Tool: DupCheckTool: DupCheck

www.DupCheck.org is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.


Project FlyerProject Flyer


Click here to download 
the NEWMEDS project flyer! 


ConsortiumConsortium
consortium teaser

QuicklinksQuicklinks
Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms




  Members Area
Username:
Password:



EU
IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

Workpackage 07

Workpackage Objectives

  • Utilize expression cohorts/data for studying cis- and trans-effects of CNVs linked to disease.
  • Advance the understanding of disease pathophysiology through brain imaging analysis of unmedicated CNV carriers which will uncover which brain functions are affected by CNVs associated with schizophrenia.
  • Advance the understanding of the disease pathophysiology through pathway analysis which will uncover new therapeutic targets linked to an improved understanding of disease biology.
  • Advance the understanding of treatment response through pathway analysis which will uncover new therapeutic targets linked to favourable treatment outcome.

Workpackage Leads

Academic Lead: Dr. Hreinn Stefánsson, deCODE Genetics Inc., Iceland
EFPIA Lead: Dr. Michael Didriksen, H. Lundbeck A/S, Denmark

Workpackage Partners

  • H Lundbeck A/S
  • King's College London 
  • deCODE Genetics Inc.
  • AstraZeneca AB
  • GlaxoSmithKline Research and Development Ltd.
  • Janssen Pharmaceutica NV
  • Pfizer Limited
  • F. Hoffmann-La Roche AG

Synergy between academia and industry

While in principle the idea of looking at genetic variants as basis of disease or response is straightforward – in practice this has not been achieved in psychiatry. A major hurdle has been that previous efforts have usually involved single groups, with small samples, using restricted ‘candidate-gene’ approaches. By bringing together deCODE and its unmatched datasets of population-based genetic data, and EFPIA with their collectively unmatched clinical samples we have a unique opportunity to go beyond the state-of-the-art. Thus, deCODE will provide variants associated with psychiatric disorders and their expression profiles whereas EFPIA will amplify these findings by providing drug response data and expression profiles before and after treatment for selected patients based on their CNV status. The final outcome of the collaboration is greater than the sum of its parts since neither deCODE nor EFPIA alone can carry out the proposed work.

WP07 - Identifying risk pathways via CNV Genetics – an emphasis on Schizophrenia